
Professor Andrew Zannettino
Pro Vice Chancellor (Health Partnerships)
Health and Medical Sciences Faculty Office
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Andrew Zannettino is the Associate Dean of Research and Professor of Experimental Haematology in the Faculty of Health Sciences, University of Adelaide and heads the Myeloma Research Laboratory (MRL) and co-heads the Regenerative Medicine Program (RMP).
The MRL’s efforts centre on identifying the molecular and cellular mechanisms responsible for myeloma disease progression and myeloma-associated bone loss.
The RMP stems from collaborative studies in association with Prof Stan Gronthos (Mesenchymal Stem Cell Laboratory, University of Adelaide) and Prof Paul Simmons (Mesoblast Ltd), which led to the patenting of technologies covering the identification and isolation of Mesenchymal Precursor Cells (MPC), a rare cell population present in many post-natal tissues.
The family of 8 patents surrounding this technology underpin the world’s largest cell therapy company, Mesoblast Ltd.
- My Research
- Career
- Publications
- Grants and Funding
- Teaching
- Supervision
- Professional Activities
- Contact
Research Interests
Myeloma is haematological malignancy characterised by the clonal proliferation of plasma cells, an immune cell type that normally protects us against infection. Myeloma is the second most common blood cancer and more than 100,000 people are diagnosed each year worldwide. Despite recent advances in treatment, myeloma remains almost universally fatal and has a 10-year survival rate of approximately 17%. The main clinical manifestations of myeloma are the development of osteolytic bone lesions, bone pain, hypercalcaemia, renal insufficiency, suppressed immunoglobulin production and increased bone marrow angiogenesis (blood vessel formation). Myeloma is preceded by a premalignant (asymptomatic) monoclonal gammopathy of uncertain significance (MGUS) stage. The factors that trigger the progression from MGUS to myeloma remain to be determined; however, our studies show that both intrinsic genetic changes and extrinsic factors play a role in disease progression. Our laboratory’s research is focussed on detecting the key signalling pathways that are deregulated during disease development and determining what microenvironmental changes occur during disease pathogenesis. We believe that these approaches will enable us to identify new molecular markers of disease risk and to design drugs against novel therapeutic targets.
Current projects are focused on
- Identifying the genetic, transcriptional and epigenetic changes that trigger the progression from asymptomatic MGUS to myeloma
- Determining why the bone marrow is a “hot-spot” for myeloma plasma cell metastasis
- Identifying the mechanisms governing dissemination and relapse in multiple myeloma
- Identifying the role played by the newly described tumour suppressor genes GLIPR1 and SAMSN1 in multiple myeloma development
- Determining the effects of myeloma plasma cells on mesenchymal stem cell differentiation.
- Assessing the effectiveness of targeting class IIa histone deacetylases (HDAC) to treat myeloma and myeloma-associated bone disease
- Identifying the role of the mTOR pathway in mesenchymal stem cell biology and bone formation.
- Assessing the effectiveness of targeting skeletal mTORC1 as a novel approach to treat diet-induced insulin resistance
Research Leadership
I provide research leadership as Associate Dean (Research), Faculty of Health Science and Laboratory Leader, Myeloma Research Laboratory, Cancer Theme, SAHMRI. As detailed herein, I also provide research leadership as a board member of a number of Institutes and Centres, member of the Assigners Academy of the NHMRC and committee member of the Medical and Scientific Advisory Group of the Australian Myeloma Foundation.
Myeloma and Bone Cancer Research
Multiple myeloma is an incurable haematological cancer of the antibody-producing plasma cell. Myeloma is unique amongst haematological malignancies in its capacity to cause massive destruction of the skeleton. The Myeloma Research Laboratory’s (MRL) efforts centre on identifying the molecular and cellular mechanisms responsible for myeloma disease progression (https://www.sahmri.com/our-research/themes/cancer/groups/mel-test-group).
Myeloma is haematological malignancy characterised by the clonal proliferation of plasma cells, an immune cell type that normally protects us against infection. Myeloma is the second most common blood cancer and more than 100,000 people are diagnosed each year worldwide. Despite recent advances in treatment, myeloma remains almost universally fatal and has a 10-year survival rate of approximately 17%. The main clinical manifestations of myeloma are the development of osteolytic bone lesions, bone pain, hypercalcaemia, renal insufficiency, suppressed immunoglobulin production and increased bone marrow angiogenesis (blood vessel formation). Myeloma is preceded by a premalignant (asymptomatic) monoclonal gammopathy of uncertain significance (MGUS) stage. The factors that trigger the progression from MGUS to myeloma remain to be determined; however, our studies show that both intrinsic genetic changes and extrinsic factors play a role in disease progression. Our laboratory’s research is focussed on detecting the key signalling pathways that are deregulated during disease development and determining what microenvironmental changes occur during disease pathogenesis. We believe that these approaches will enable us to identify new molecular markers of disease risk and to design drugs against novel therapeutic targets.
The MRL has made a significant contribution to the field in relation to
- Mechanisms of myeloma associated bone loss
- Identifying the genetic, transcriptional and epigenetic changes that trigger the progression from asymptomatic MGUS to myeloma
- Determining why the bone marrow is a “hot-spot” for myeloma plasma cell metastasis
- Identifying the mechanisms governing dissemination and relapse in multiple myeloma
- Identifying the role played by the newly described tumour suppressor genes GLIPR1 and SAMSN1 in multiple myeloma development
- Identifying how myeloma plasma cells affect mesenchymal stem cell differentiation.
- The effectiveness of targeting class IIa histone deacetylases (HDAC) to treat myeloma and myeloma-associated bone disease
- Identifying a role for the mTOR pathway in mesenchymal stem cell biology and bone formation.
- Assessing the effectiveness of targeting skeletal mTORC1 as a novel approach to treat diet-induced insulin resistance
Therapeutic Use of Mesenchymal Progenitor Cells
Mesenchymal Progenitor Cells (MPC) are rare stem cells present within post-natal tissues which possess promising therapeutic properties. In the late 90’s, collaborative studies in association with Prof Stan Gronthos (Mesenchymal Stem Cell Laboratory, UA/SAHMRI) and Professor Paul Simmons (Mesoblast Ltd.) led to the patenting of technologies covering the identification and isolation of these rare cells from bone marrow. The family of 8 patents surrounding this technology were assigned to Angioblast Systems Inc., New York, USA in November, 2004 facilitating the formation of Mesoblast Ltd, an Australian Stock Exchange listed company (http://www.mesoblast.com). In return for the assignment of these patents, the IMVS/Medvet/SA Pathology (my substantive employer at that time) received a significant parcel of shares in this company. Since January 2005, Prof Gronthos and I have served as consultants to both Angioblast Systems Inc. and Mesoblast Ltd. and our laboratories have continued to receive funding to support the improvement/development of existing/new intellectual property and to fund large pre-clinical animal models of disease.
Research Collaborations
My expertise in the fields described above has led to active collaborations with scientists/clinicians throughout the world as detailed below.
In 1994-1995, I developed a powerful retroviral-based expression cloning strategy to enable isolation of genes encoding cell surface molecules that participate in intercellular interactions. This methodology has lead to numerous collaborations and ongoing consultation work with scientists including:
- Dr H-J. Buhring, University of Tubingen, Germany, Retroviral Expression cloning of cell surface antigens expressed by normal and leukaemic haemopoietic stem cells;
- Prof. Leonie K. Ashman, University of Newcastle, Retroviral Expression cloning of drug resistance genes;
- Prof. James T. Triffit, Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Oxford, UK, Retroviral Expression cloning of osteoblast-related cell surface antigens;
- Dr S. Watt, MRC Molecular Haematology Unit, The Institute of Molecular Medicine, University of Oxford, UK, Retroviral Expression cloning of novel cell surface molecules.
My research into myeloma-associated bone loss and molecular mechanisms of myeloma disease pathogenesis has led to further collaborations with a number of academic and industry-based scientists including:
- Prof. John Shaughnessy, Formerly of University of Arkansas, Little Rock, Arkansas, USA and founder of SignalGeneticsTM, Carlsbad, CA. The role of DKK-1 in myeloma-associated bone loss;
- Dr Daniel Peet, Department of Bichemistry, Molecular Life Sciences, University of Adelaide: Role of CXCL12 (SDF-1)/CXCR4 in Pathological Angiogenesis and Osteolytic Bone Disease in Multiple Myeloma;
- Dr Phil Kearney, Santaris Pharma, Copenhagen, Denmark: Role of CXCL12 (SDF-1)/CXCR4 in Pathological Angiogenesis and Osteolytic Bone Disease in Multiple Myeloma;
- Prof. Nobutaka Fujii and Prof. Hirokazu Tamamura, Graduate School of Pharmaceutical Sciences Kyoto University Department of Bioorganic Medicinal Chemistry, JAPAN, Role of SDF-1 in myeloma;
- A/Prof. Kevin Lynch, Novartis, Sydney, Australia, Tyrosine Kinase Inhibition as a Potential Modality to Control Osteolytic Bone Disease: A New Role for Imatinib Mesylate and Second Generation Bcr-Abl Inhibitors;
- Dr Elisabeth Buchdunger and Dr Paul Manley, Novartis Pharma, Skeletal Effects of the Abl Kinase Inhibitors, Nilotinib and Imatinib;
- Dr Francis Lee and Dr Richard Smykla, Bristol-Myers Squibb, Skeletal Effects of the Abl Kinase Inhibitors, Dasatinib;
- Prof. Vijay Modur, Novartis Pharmaceuticals Corporation, Cambridge, MA, USA. Novel mediators of multiple myeloma metastases to the bone;
- Prof. William Dougall, Amgen, Seattle, Washington, USA, The role of RANKL in myeloma-associated bone loss;
- Prof. Peter Croucher, Bone Biology Laboratory, Bone Biology Division, Garvan Institute of Medical Research, NSW, AUS. The role of the bone marrow microenvironment in the pathogenesis of myeloma;
- Dr Daniel Worthley, University of Adelaide, Adelaide, Australia, The role of the bone marrow microenvironment in the pathogenesis of myeloma;
- Prof. Siddhartha Mukherjee, Columbia University, NY, USA. The role of the bone marrow microenvironment in the pathogenesis of myeloma;
- Prof. Orest Blaschuk, Urology Research Laboratories, Division of Urology, McGill University Health Centre, Canada. The use of Cadherin antagonists to treat multiple myeloma;
- Prof. Jonathan Licht, University of Florida Cancer Centre. The role of EMT in myeloma disease dissemination and disease progression;
- Prof. Ricky Johnstone, Gene Regulation Laboratory, Peter MacCallum Cancer Centre, The role of the bone marrow microenvironment in the pathogenesis of myeloma;
- Associate Professor Simon Leedham, Wellcome Trust Centre for Human Genetics, Oxford, The role of the bone marrow microenvironment in the pathogenesis of myeloma;
- Prof. Charles Mullighan, Hematological Malignancies Program, St. Jude Children’s Research Hospital, Understanding clonal evolution in multiple myeloma;
- Prof. Gareth Morgan, University of Arkansas, Myeloma Institute for Research and Therapy (UAMS), Understanding clonal evolution in multiple myeloma.
My research into physiological and aberrant bone remodelling and novel skeletally-derived factors that regulate glucose metabolism has led to collaborations with a number of academic and industry-based scientists including:
- Prof. D.M. Findlay and Dr Gerald J. Atkins and Dr. Andreas Evdokiou, Discipline of Orthopaedics and Trauma, Royal Adelaide Hospital and the University of Adelaide. Normal and pathological bone remodelling;
- Dr. Andreas Evdokiou, Discipline of Surgery, Basil Hetzel Institute for Translational Health Research and the University of Adelaide. Bone cancer and bone cancer metastasis;
- Dr Colin Dunstan, University of Sydney and formerly of Amgen Inc, CA, USA; The Role of OPG in bone metabolism;
- Dr Peter J Anderson and Prof David David, Child Health Research Institute and The Women’s and Childrens Hospital, Adelaide, South Australia: Mechanisms of premature cranial fusion and development of novel adjunct approaches to treatment;
- Prof H. Zreiqat, School of Pathology, University of New South Wales, Sydney, Australia, Behaviour of osteoclasts and bone cells on bio-material surfaces;
- Prof D. R. Haynes, Department of Pathology, University of Adelaide, Adelaide, South Australia, The role of TNF family members TWEAK and TNF-alpha in bone remodelling;
- A/Prof Sofianos Andrikopoulos, The University of Melbourne, The University of Melbourne, Skeletal endocrine signalling in the regulation of glucose metabolism;
- Dr Paul Baldock, Garvan Institute of Medical Research, Garvan Institute of Medical Research, The University of New South Wales, Skeletal endocrine signalling in the regulation of glucose metabolism;
- Prof Christopher Proud, South Australian Health and Medical Research Institute, SA, AUS, Targeting skeletal mTORC1 as a novel approach for the treatment of diet-induced insulin resistance.
My research into mesenchymal precursor cell biology and application has led to collaborations with a number of biotechnology companies, including Angioblast Systems Inc., Mesoblast Ltd. and Genzyme International. In addition, I also collaborate and consult for a number of academic scientists including:
- Prof. Silviu Itescu, University of Melbourne and Columbia University's New York -Presbyterian Hospital in New York, USA and Angioblast Systems Inc and Mesoblast Ltd.: Clinical Application of Mesenchymal Precursor Cells for bone repair, articular cartilage regeneration, disc cartilage regeneration, cellular therapy of heart attack/heart failure, peripheral arterial disease and wound ulcers;
- A/Prof. Robert Moore, Formerly head of the Adelaide Centre for Spinal Research, Institute of Medical and Veterinary Science, Adelaide, South AUSTRALIA: A Preclinical trial of the potential for cultured mesenchymal precursor cells to restore extracellular matrix and normal mechanical function to degenerate intervertebral discs;
- Prof. Peter Ghosh, Institute of Nutraceutical Research, Brookevale, NSW, Australia: Cartilage Regenerative Potential of Ovine Mesenchymal Precursor Cells (MPC);
- A/Prof John Field, Flinders University of South Australia, School of Medicine, Bedford Park, South Australia: Evaluation of the safety and efficacy of Allogeneic Mesenchymal Progenitor Cells (MPC) for the repair of critical size defects in an ovine tibial model;
- Prof. Stephen Worthley, Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, South Australia: A study of the cardiac regenerative potential of immunoselected ovine bone marrow mesenchymal stem cells;
- Dr Cory Xian and Prof. Bruce Foster, Bone Growth Foundation, Department of Orthopaedic Surgery, Women's and Children's Hospital. Molecular pathways for the bony repair of injured growth plate cartilage;
- Prof. Richard Read, Evaluation of the safety and efficacy of Allogeneic Mesenchymal Progenitor Cells (MPCs) in the regeneration of a medial knee joint meniscus and the retardation of cartilage injury in an ovine model of osteoarthritis;
Since 2005, I have been a scientific consultant for Mesoblast Ltd. where I have helped consolidate and expand our stem cell based technology patent family and have successful completed key milestones such as the development of a MSC isolation and culture expansion standard operational protocol within a GMP facility. This has resulted in an increase in capital investor funding to support the commencement of several phase II/III cardiac and orthopaedic clinical studies. Funds from Mesoblast Ltd have been used to continue basic R&D in our laboratory and for initiating new pre-clinical animal studies within the IMVS/ Hanson Institute/ RAH/ University of Adelaide campuses. Collectively, these studies have formed the foundation of new IND (investigative new drug) applications submissions to the USA FDA for future phase I/II/III human clinical trials involving different health centres and laboratories in Adelaide, Australia and the USA.
Research Output
I have co-authored more than 177 refereed publications, book chapters and review articles (not including published abstracts). Many of these articles are published in premier Haematology and Orthopaedic journals (BLOOD, Leukemia, BJH, JBMR, Bone), Cancer journals (Cancer Research, Clinical Cancer Research) and Stem Cell journals (Cell Stem Cell, Stem Cells). My publications have received in excess of 9800 citations and his H Factor = 51. Refer to Publications section for full details.
Presentations
I have has been invited to present my laboratory’s findings at more than 40 national and international forums since 2010. In addition, I have co-authored more than 75 abstracts with more than 55 of these being published as Meeting Proceedings.
Year | National/ International | Event Title | Role |
---|---|---|---|
2016 |
National |
New Directions in Leukaemia Research meeting March 16-19, 2016, Noosa, QLD, AUS |
Invited Speaker |
2015 |
International |
"PACIFICHEM 2015 Conference December 15-20, 2015 in Honolulu, HI." |
Invited Speaker |
2014 |
International |
American Society of Haematology |
Invited Speaker |
2014 |
National |
Sydney Cancer and Bone Meeting |
Invited Speaker |
2013 |
International |
Australian and New Zealand Bone and Mineral Society |
Invited Speaker |
2013 |
National |
Frontiers in Skeletal Biology |
Invited Speaker |
2012 |
National |
Combio 2012 |
Invited Speaker |
2012 |
National |
SA Multiple Myeloma Interest Group |
Invited Speaker |
2012 |
National |
SVRI-Seminar Series |
Invited Speaker |
2012 |
National |
The Australian Health and Medical Research Congress |
Invited Speaker |
2011 |
International |
Austalian and New Zealand Bone and Mineral Research |
Plenary Speaker |
2010 |
National |
Adelaide Bone Group Meeting |
Invited Speaker |
2010 |
International |
American Society of Haematology |
Session Chair |
2010 |
National |
Annual HSANZ - SA “Blood Club Meeting”, |
Invited Speaker |
2010 |
National |
Leukaemia Foundation of Australia – Myeloma Awareness Day |
Invited Speaker |
2009 |
International |
Asia Pacific Haematology Summit |
Keynote Speaker |
2009 |
International |
HAA 2009; 2009 Annual Scientific Meeting of HSANZ, ANZSBT, ASTH |
Keynote Speaker |
2009 |
National |
Health Development Adelaide Symposium |
Presenter |
2009 |
International |
Janssen Cilag, Multiple Myeloma 3 (MM3) meeting |
Presenter |
2009 |
International |
Novartis APECHO-APTM Workshop |
Keynote Speaker |
2008 |
International |
American Society of Haematology |
Poster Presenter |
2008 |
National |
Bio Innovation SA Networking Forum – Bio Innovation Osteo Networking Evening |
Keynote Speaker |
2008 |
International |
Fifth Clare Valley Bone Meeting |
Keynote Speaker |
2008 |
National |
NCRIS 5.5 CGMP - SEMINAR/WORKSHOP - “NANO-ENGINEERING FOR CELLS” |
Presenter |
2008 |
National |
Royal Adelaide Hospital Medical Grand Round |
Presenter |
2007 |
National |
Barbara Ell Seminar Series, Victor Chang Cardiac Research Institute |
Presenter |
2007 |
International |
Novartis Oncology Research and Development Symposium |
Presenter |
2007 |
National |
2007 Mater Medical Research Institute Symposium |
Presenter |
2006 |
International |
American Society of Haematology |
Session Chair |
2006 |
National |
Department of Orthopaedics and Trauma, Royal Melbourne Hospital |
Presenter |
2006 |
National |
Inaugural Tissue Engineering Symposium (SuTEN), Biomedical Engineering at Sydney University School of Aerospace, Mechanical and Mechatronic Engineering and The Bosch Institute |
Presenter |
2006 |
International |
Novartis Oncology Australia, Research and Development Symposium, The Intercontinental Hotel |
Keynote Speaker |
2005 |
National |
ANZ Matrix Biology Society Conference, Whalers Inn, Victor Harbour, SA |
Keynote Speaker |
2005 |
National |
Department of Genetic Medicine, Womens and Children’s Hospital |
Presenter |
2005 |
National |
Division of Molecular Pathology, IMVS |
Presenter |
2005 |
National |
The Basil Hetzel Institute, The Queen Elizabeth Hospital |
Presenter |
2004 |
International |
Haematology Society of Australia and New Zealand, Exhibition and Convention Centre |
Presenter |
2003 |
National |
Adelaide Blood Club |
Invited Speaker |
2003 |
National |
Division of Clinical Biochemistry, IMVS |
Invited Speaker |
2003 |
National |
Division of Molecular Pathology, IMVS |
Invited Speaker |
2003 |
National |
Division of Pathology, IMVS |
Invited Speaker |
2003 |
National |
The Alfred Hospital |
Invited Speaker |
2002 |
International |
Australian and New Zealand Orthopaedic Research Society |
Invited Speaker |
2002 |
National |
Child Health Research Institute |
Invited Speaker |
2002 |
National |
Department of Medicine, University of Adelaide |
Invited Speaker |
2002 |
National |
Molecular Biology of Skeleton |
Invited Speaker |
2001 |
National |
Adelaide Blood Club |
Invited Speaker |
2001 |
International |
Molecular Mechanisms of Skeletal Disease mediated by Myeloma, NIH |
Invited Speaker |
2001 |
International |
Zymogenetics |
Invited Speaker |
1998 |
International |
Australian and New Zealand Orthopaedic Research Society |
Invited Speaker |
1998 |
International |
Haematology Society of Australia and New Zealand |
Invited Speaker |
1998 |
National |
Hanson Symposium |
Invited Speaker |
Additional Evidence of Research Leadership
When I joined the UA School of Medical Sciences (SoMS), I served as a member of the Research Committee. In January 2014, I was appointed as Chair of this committee, and immediately instituted 4 new funding programs designed to drive research activity, including an ECR “kick start” award, a strategic equipment fund, an ECR/MCR travel award and a publication award program.
I was also appointed to the SoMS board, the FHS Research Committee and was the Deputy Chair of the Adelaide Medical and Nursing School (AMNS) Project Committee overseeing the construction of a new $230 million Medical/Nursing/Research facility in the new West End Biomedical Research Precinct which will house approximately 350 Researchers. In January 2015, I was appointed to Deputy Head, SoMS. In March 2015, the Executive Dean, Professor Alastair Burt appointed me to establish and chair the Research Strategy Taskforce (RSTF). The RSTF was charged with the responsibility of devising a new research strategy to promote research excellence within the FHS. This work has led to the development of an adaptable strategic framework to enhance research education (HDR/honours), develop research strengths, build enabling technologies/research infrastructure and develop pathways to improved health care and the generation of valuable intellectual property.
My national standing in the fields of cell and cancer biology has been recognised by my appointment to the NHMRC Grant Review Panel (GRP) for Cell biology (2005, 2006) and Oncology (2010) and Assigners Academy (2014, 2015, 2016). In recognition of my international standing in the field of myeloma-associated bone loss, I was invited by the Leukaemia Research Fund (LRF) of UK, to participate in a “site visit” of Myeloma Program of Prof. Peter Croucher, University of Sheffield, UK, to assess his application for program funding through the LRF in both 2006 and 2009. In addition, I was invited to participate as a moderator for the 2006 American Society of Haematology (ASH) Annual Meeting, for the session titled “Multiple Myeloma: Microenvironment”. Recently, I was invited to be an Abstract Reviewer of the “Myeloma-Pathophysiology and Preclinical studies excluding Therapy” Category for the 52nd Annual Meeting of the ASH, a prestigious appointment bestowed upon recognized experts in the field.
As a testament to my expertise in my chosen fields, I have been asked to present my laboratories findings at numerous scientific meetings and institutions (see “Conference Presentations”) and I have been asked to contribute to numerous review articles and book chapters (see “Publications”). As a recognised expert in the areas of skeletal, stem and cancer biology, I am asked to review >3 manuscripts per month for more that 20 journals including BLOOD, Leukemia, Leukemia and Lymphoma, Experimental Hematology, Haematologica, Journal of Bone and Mineral Research, Leukemia, Cell Stem Cell, Clinical Cancer Research, Cancer Research, International Journal of Cancer, Bone, FASEB Journal. I am also regularly asked to review applications for a number of funding bodies including the NHMRC, Cancer Council of South Australia, Cure Cancer Australia and Leukaemia Research Fund (UK). Most recently, I was approached by the Wiley-Blackwell publishing house to assess the merits of publication of a book entitled: “Stem Cells: Science and Business Strategies” by A. Vertes et al.
As further evidence of my scientific standing, I have served on organising committees involved in staging both national and international scientific meetings including; the 2004 Hanson Symposium Stem Cell Meeting (Adelaide, SA, 2004); the 10th International Myeloma Congress (Sydney, NSW, 2005); the Clare Bone Meeting (Clare Valley, SA, 2006). I represented the Centre for Cancer Biology (CCB) as a Subject Matter Expert (SME) charged with the role of identifying the facilities requirements for the South Australian Health and Medical Research Institute (SAHMRI). Finally, I have served on the Fellowships and Scholarships Committee for the Leukaemia Foundation of Australia.
Clinical Outcomes of Research
As a member of MSAG, I have provided guidance on both myeloma and supportive treatment strategies and have co-authored guidelines for the safe use of bisphosphonates (Dickinson M et al, Intern Med J. 2009. May;39(5):304-16) and Clinical Practice Guidelines (Quach H et al, in preparation, 2010). Furthermore, my work has raised the awareness amongst clinicians of the importance of routine examination of CTX levels in patients. CTX (the C-telopeptide of the α1 chain of collagen type 1), a reliable marker of bone turnover, is now being used locally as a routine test for all myeloma patients at diagnosis and restaging. CTX, when used in conjunction with paraprotein levels and bone marrow assessment can detect early progression of myeloma. This is a palpable achievement and one that has led to better outcomes for patients.
As a co-inventor of the Mesenchymal Progenitor Cell (MPC) cellular therapy, I have been instrumental in developing a therapy that is likely to have a significant impact in the areas of spinal fusion, osteoarthritis, congestive heart failure, heart attacks, eye diseases, diabetes, and bone marrow repair.
Patents
I am a co-inventor of 8 patents that describe the isolation and composition of matter of mesenchymal precursor cells (MPC), a unique population of adult stem cells with tissue reparative properties. This family of patents were assigned to Angioblast Systems Inc., New York, USA in November, 2004 facilitating the formation of Mesoblast Ltd, an Australian Stock Exchange listed company. In 2010, Mesoblast acquired Angioblast Systems Inc forming the Mesoblast Group.
Year | Patent Number | Patent Office | Status |
---|---|---|---|
2008 | US 61/189,349 | United States of America | Under Examination |
2006 | PCT/AU2006/000494 | United States of America | Under Examination |
2004 | PCT/AU2005/001445 | United States of America | Granted |
2004 | PCT/AU2005/000953 | United States of America | Granted |
2003 | WO 2004/085630 | United States of America | Granted |
2003 | WO 2004/084921 | Australia | Granted |
1999 | WO 01/04268A1 | United States of America | Granted |
1997 | WO9707204 | United States of America | Granted |
1997 | JP9188700 | Japan | Granted |
-
Expand
-
Appointments
Date Position Institution name 2015 Principal Senior Research Fellow SAHMRI 2012 Associate Dean, Research University of Adelaide 2012 Professor of Experimental Haematology University of Adelaide 2011 Affiliate Professor University of Adelaide 2010 Chief Medical Scientist and Head of the Research Unit SA Pathology / Institute of Medical and Veterinary Science 2010 ASH Abstract Reviewer American Society of Haematology 2008 - 2012 Research Manager SA Pathology/Institute of Medical and Veterinary Science 2008 - 2012 Co-Head, Regenerative Medicine Program Institute of Medical and Veterinary Science 2007 - 2012 Chief Medical Scientist, Laboratory Head and Research Manager SA Pathology/Institute of Medical and Veterinary Science 2007 - 2010 Affiliate Associate Professor University of Adelaide 2006 - 2012 Head of the Myeloma Research Program Institute of Medical and Veterinary Science 2005 Site reviewer University of Sheffield, Leukemia Foundation - United Kingdom 2004 - 2006 Principle Medical Scientist and Laboratory Head Institute of Medical and Veterinary Science/Hanson Institute 2000 - 2003 Senior Medical Scientist Institute of Medical and Veterinary Science/Hanson Institute 1997 - 1999 NH&MRC Research Officer Institute of Medical and Veterinary Science -
Awards and Achievements
Date Type Title Institution Name Country Amount 1999 Award Young Investigator Award Hanson Centre for Cancer Research Australia — 1998 Award Johnson and Johnson Young Investigator award Australian and New Zealand Orthopaedics Research Society Australia — 1992 Award Postgraduate Scholarship Award University of Adelaide Australia — -
Education
Date Institution name Country Title 1997 University of Adelaide Australia PhD 1992 University of Adelaide Australia Honours (First Class) 1991 University of Adelaide Australia BSc (Hons) -
Research Interests
-
Expand
-
Journals
-
Book Chapters
-
Conference Papers
Year Citation 2019 Arthur, A., Paton, S., Gronthos, S., & Zannettino, A. (2019). The Loss of ephrinB1 in Osteoprogenitors Delays Fracture Repair. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 34 (pp. 326). Orlando, FL: WILEY. 2018 Tangseefa, P., Martin, S. K., Wilczek, V., Baldock, P., Proud, C. G., Fitter, S., & Zannettino, A. C. (2018). Metabolic and reproductive abnormalities in mice with impaired skeletal-mTORC1 function mirror a dietary restriction phenotype. In CLINICAL ENDOCRINOLOGY Vol. 89 (pp. 19). Perth, AUSTRALIA: WILEY. 2018 Camp, E., Anderson, P., Zannettino, A., & Gronthos, S. (2018). Inhibition of tyrosine kinase receptor C-ROS-1 as a novel treatment for patients with TWIST haploinsufficiency induced craniosynostosis. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 33 (pp. 424). Montreal, CANADA: WILEY. 2017 Zeissig, M. N., Hewett, D. R., Martin, S., Mrozik, K. M., Cheong, C. M., Diamond, P., . . . Zannettino, A. C. W. (2017). HIF-2 alpha Upregulates CCR1 to Promote Dissemination of Plasma Cells in Multiple Myeloma. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY. 2016 Asari, K., Heatley, S. L., Sadras, T., Leclercq, T. M., Fitter, S., Kok, C. H., . . . White, D. L. (2016). In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance Implications for Targeted Therapy. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY.
2016 Ebert, L., Tan, L., Min, K., Cockshell, M., Johan, M., Parham, K., . . . Bonder, C. (2016). Desmoglein 2 (DSG2) is a novel surface marker of endothelial and haematopoietic progenitor cells, and plays a critical role in neoangiogenesis. In EUROPEAN JOURNAL OF IMMUNOLOGY Vol. 46 (pp. 309). Melbourne, AUSTRALIA: WILEY-BLACKWELL. 2016 Nguyen, T., Arthur, A., Purton, L., Hayball, J., Zannettino, A., Paton, S., . . . Gronthos, S. (2016). EphB4 enhances bone marrow stromal stem cell-mediated support of haematopoiesis. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 173 (pp. 30). British Soc Haematol, Glasgow, SCOTLAND: WILEY-BLACKWELL. 2014 Vandyke, K., Mrozik, K. M., Cheong, C. M., Chow, A. W. S., Kok, C. H., Blaschuk, O., . . . Zannettino, A. C. W. (2014). Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. In BLOOD Vol. 124 (pp. 3 pages). San Francisco, CA: AMER SOC HEMATOLOGY. 2013 Forristal, C. E., Helwani, F., Martin, S., Nowlan, B., Winkler, I. G., Zannettino, A., & Levesque, J. -P. (2013). Hypoxia Inducible Factor (HIF)-2 alpha Enhances Proliferation Of Malignant Hematopoietic Cells In The Hypoxic Malignant Bone Marrow. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS12013 Noll, J., Williams, S., Vandyke, K., Kok, C., & Zannettino, A. (2013). IDENTIFICATION AND CHARACTERISATION OF THE ROLE OF SAMSN1 GENE EXPRESSION IN A MURINE MODEL OF MYELOMA AND MYELOMA PATIENTS. In HAEMATOLOGICA Vol. 98 (pp. 316). FERRATA STORTI FOUNDATION. 2013 Noll, J., Williams, S., Tong, C., Wang, H., Purton, L., Farrugia, A., . . . Zannettino, A. (2013). MYELOMA PLASMA CELLS ALTER THE BONE MICROENVIRONMENT BY STIMULATING AN INCREASE IN MESENCHYMAL STEM CELLS: A COMPARATIVE STUDY OF MYELOMA PATIENT- AND MURINE MODEL-DERIVED MESENCHYME. In HAEMATOLOGICA Vol. 98 (pp. 95). FERRATA STORTI FOUNDATION. 2011 Zannetino, A. (2011). PATHOPHYSIOLOGY OF BONE DISEASE IN MULTIPLE MYELOMA. In OSTEOPOROSIS INTERNATIONAL Vol. 22 (pp. S508). Gold Coast, AUSTRALIA: SPRINGER LONDON LTD. 2011 Arthur, A., Panagopoulos, R., Cooper, L., Zannettino, A., Koblar, S., Sims, N., . . . Gronthos, S. (2011). THE ROLE OF EPHB/EPHRINB MOLECULES IN FRACTURE REPAIR. In OSTEOPOROSIS INTERNATIONAL Vol. 22 (pp. S523). Gold Coast, AUSTRALIA: SPRINGER LONDON LTD. 2011 Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Diamond, P., Findlay, D., . . . Evdokiou, A. (2011). Local production of osteoprotegerin by breast cancer cells inhibits cancer-induced osteolysis and intra-osseous tumour burden but fails to restrain extra-medullary tumour growth. In BONE Vol. 48 (pp. S256). Athens, GREECE: ELSEVIER SCIENCE INC.
2010 Nath, S. V., Tamblyn, M., Telfer, S., Henwood, T., Gilham, P., Story, C., . . . Revesz, T. (2010). Ethylene Diamine Tetra Acetic Acid (EDTA) Decalcification of Paediatric Bone Marrow Trephines In a Diagnostic Laboratory. In BLOOD Vol. 116 (pp. 1062). Orlando, FL: AMER SOC HEMATOLOGY. 2009 McCarty, R. C., Gronthos, S., Zannettino, A. C., Foster, B. K., & Xian, C. J. (2009). Characterisation of ovine bone marrow derived mesenchymal stromal/stem cells and autologous application to growth plate cartilage defect. In BONE Vol. 45 (pp. S106-S107). Cambridge, ENGLAND: ELSEVIER SCIENCE INC.
2009 McCarty, R. C., Gronthos, S., Zannettino, A. C., Foster, B. K., & Xian, C. J. (2009). Characterisation of ovine bone marrow derived mesenchymal stem cells and autologous application to growth plate cartilage defect. In BONE Vol. 44 (pp. S159). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC.
2009 Macsai, C., Hopwood, B., Zannettino, A. C., Scherer, M. A., Foster, B. K., & Xian, C. J. (2009). Micro-CT and micro-array analyses of growth plate cartilage injury responses and bony repair. In BONE Vol. 44 (pp. S152). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC.
2009 Psaltis, P. J., Worthley, S. G., See, F., Itescu, S., Martens, T., Gronthos, S., & Zannettino, A. (2009). Enrichment for Stro-1 Enhances Paracine-mediated Cardiovascular Repair From Human Bone Marrow Mesenchymal Cells. In CIRCULATION Vol. 120 (pp. S821). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS. 2009 Zinonos, I., Labrinidis, A., Liapis, V., Hay, S., Lee, M., Ponomarev, V., . . . Evdokiou, A. (2009). Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumour growth and osteolysis in murine models of breast cancer development and progression. In BONE Vol. 44 (pp. S54). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC.
2009 Psaltis, P. J., Carbone, A., Manavis, J., Jantzen, T., Lau, D., Sanders, P., . . . Worthley, S. G. (2009). Catheter-based Electromechanical Mapping Accurately Characterizes Segmental Distribution of Left Ventricular Fibrosis in Nonischemic Cardiomyopathy. In CIRCULATION Vol. 120 (pp. S906). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS. 2009 Psaltis, P. J., Zannettino, A., Carbone, A., Manavis, J., Williams, K., Jantzen, T., . . . Worthley, S. G. (2009). Cardiac Repair With Transendocardial Injection of Allogeneic Mesenchymal Precursor Cells for Nonischemic Cardiomyopathy. In CIRCULATION Vol. 120 (pp. S827). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS. 2009 Gronthos, S., Isenmann, S., Arthur, A., Zannettino, A. C. W., Shi, S., & Glackin, C. A. (2009). The role of Twist-1 and-2 in the maintenance of mesenchymal stromal/stem cells. In BONE Vol. 44 (pp. S146). Sydney, AUSTRALIA: ELSEVIER SCIENCE INC.
2009 Engler, J. R., Frede, A., Saunders, V. A., Zannettino, A. C. W., White, D. L., & Hughes, T. P. (2009). OCT-1 Activity in CML CD34+Cells Is Not Predictive of Molecular Response to Imatinib Treatment in CP-CML Patients, Despite the Strong Predictive Value of MNC OCT-1 Activity. In BLOOD Vol. 114 (pp. 861). New Orleans, LA: AMER SOC HEMATOLOGY. 2008 Engler, J. R., Frede, A., Zannettino, A. C., White, D. L., & Hughes, T. P. (2008). Reduced Activity of the OCT-1 Protein in Primitive CML Cells: A Likely Determinant of Stem Cell Resistance in Imatinib Treated CML Patients. In BLOOD Vol. 112 (pp. 80). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS22008 Martin, S., Diamond, P., To, L., Pect, D., Gronthos, S., & Zannettino, A. (2008). CXCL12 Expression Is Regulated by HIF-2a in Multiple Myeloma Plasma Cells. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 23 (pp. S262). Montreal, CANADA: AMER SOC BONE & MINERAL RES. 2008 Freeman, L. M., Petcu, E., Smith, R., Salajegheh, A., Diamond, P., Zannettino, A. C. W., . . . Vuckovic, S. (2008). Depletion of Host CD122(+) Cells Facilitates Widespread Skeletal Multiple Myeloma Engraftment in NOD/SCID Recipients.. In BLOOD Vol. 112 (pp. 945). San Francisco, CA: AMER SOC HEMATOLOGY. 2008 Diamond, P., Labrinidis, A., Martin, S., Gronthos, S., To, L., Fuji, N., . . . Zannettino, A. (2008). Elevated Serum Levels of CXCL12 Is Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 23 (pp. S262). Montreal, CANADA: AMER SOC BONE & MINERAL RES. 2008 Vandyke, K., Dewar, A., Diamond, P., Fitter, S., Farrugia, A. N., To, L. B., . . . Zannettino, A. C. W. (2008). Dasatinib (Sprycel (TM)) Inhibits Oteoclast Activity in Vitro and in Vivo Via a C-Fms-Dependent and C-Src-Independent Mechanism. In BLOOD Vol. 112 (pp. 1102-1103). San Francisco, CA: AMER SOC HEMATOLOGY. 2008 Diamond, P., Labrinidis, A., Martin, S. K., Farrugia, A., Gronthos, S., To, L. B., . . . Zannettino, A. (2008). CXCL12 stimulates osteoclastic bone resorption in a novel mouse model of human multiple myeloma. In Journal of Bone and Mineral Research Vol. 23 (pp. S262). Montreal: American Society for Bone and Mineral Research. 2007 Martin, S. K., Dewar, A., Farrugia, A., Horvath, N., Gronthos, S., To, L. B., & Zannettino, A. (2007). Tumour angiogenesis is associated with plasma levels of stromal-derived factor-1a in patients with multiple myeloma. In Haematologica Vol. 92 (pp. 125-126). Kos, Greece: Ferrata Storti Foundation. 2007 Diamond, P., Labrinidis, A., Martin, S., Farrugia, A., Gronthos, S., To, L., . . . Zannettino, A. (2007). CXCL12 stimulates osteoclastic bone resorption in a novel mouse model of human multiple myeloma. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 130). Kos Isl, GREECE: FERRATA STORTI FOUNDATION. 2007 See, F., Seki, T., Psaltis, P., Martens, T., Gronthos, S., Worthley, S., . . . Itescu, S. (2007). Human stroll mesenchymal precursor cells induce proliferative effects on vascular smooth muscle cells and endothelium via P13 kinase dependent pathways. In CIRCULATION Vol. 116 (pp. 104). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS. 2007 Martin, S., Dewar, A., Farrugia, A., Horvath, N., Gronthos, S., To, L., & Zannettino, A. (2007). Tumour angiogenesis correlates with plasma levels of CXCL12 in patients with multiple myeloma. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 125-126). Kos Isl, GREECE: FERRATA STORTI FOUNDATION. 2006 White, D., Dang, P., Venables, A., Saunders, V., Zrim, S., Zannettino, A., . . . Hughes, T. (2006). ABCB1 overexpression may predispose imatinib treated CML patients to the development of Abl kinase domain mutations, and may be an important contributor to acquired resistance.. In BLOOD Vol. 108 (pp. 608A). Orlando, FL: AMER SOC HEMATOLOGY.
WoS22006 White, D., Saunders, V., Dang, P., Venables, A., Zrim, S., Reynolds, J., . . . Hughes, T. (2006). Molecular response to imatinib is dependent on dose in CML patients with low OCT-1 influx activity. Patients with high activity may respond equally well to standard or increased dose imatinib.. In BLOOD Vol. 108 (pp. 222A). Orlando, FL: AMER SOC HEMATOLOGY. 2005 Zannettino, A., Kortesidis, A., Farrugi, A., & Gronthos, S. (2005). The role of stromal derived factor-1 alpha in bone remodelling.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 20 (pp. S368). Nashville, TN: AMER SOC BONE & MINERAL RES. 2005 Atkins, G., Kostakis, P., Vincent, C., Farrugia, A., Findlay, D., Evdokiou, A., & Zannettino, A. (2005). RANK expression in normal and malignant haemopoietic cells: A monoclonal antibody study.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 20 (pp. S146). Nashville, TN: AMER SOC BONE & MINERAL RES. 2005 White, D., Saunders, V., Engler, J., Dang, P., Zannettino, A., Cambareri, A., . . . Hughes, T. (2005). Low baseline intrinsic sensitivity to imatinib (high IC50) in CML patients is due to reduced Oct-1 mediated influx. Intrinsic sensitivity to AMN107 does not correlate with that of imatinib and uptake of AMN107 is not Oct-1 mediated.. In BLOOD Vol. 106 (pp. 315A). Atlanta, GA: AMER SOC HEMATOLOGY. 2005 Kostakis, P., Atkins, G., Vincent, C., Farrugia, A., Findlay, D., Evdokiou, A., & Zannettino, A. (2005). RANK expression in normal and malignant cells: a monoclonal antibody study. In Journal of Bone and Mineral Research Vol. 20 (pp. SA-259.). Nashville, Tennessee: American Society for Bone and Mineral Research. 2004 Atkins, G., Anderson, P., Welldon, K., Zannettino, A., Morris, H., & Findlay, D. (2004). Vitamin D metabolism in human osteoblasts. In Journal of Bone and Mineral Research Vol. 19 (pp. SA-587). Seattle, Washington: American Society for Bone and Mineral Research. 2004 Martens, T., Schuster, M., See, F., Xydas, S., Hefti, M., Gronthos, S., . . . Itescu, S. (2004). Human mesenchymal precursors induce myocardial arteriogenesis and global functional recovery after myocardial ischemia. In CIRCULATION Vol. 110 (pp. 70). New Orleans, LA: LIPPINCOTT WILLIAMS & WILKINS. 2004 Atkins, G. J., Anderson, P. H., Welldon, K., Zannettino, A. C. W., Morris, H. A., & Findlay, D. M. (2004). Vitamin D metabolism in human osteoblasts.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 19 (pp. S204). Seattle, WA: AMER SOC BONE & MINERAL RES. 2003 Atkins, G. J., Anderson, P. H., Morris, H. A., Zannettino, A. C. W., Kostakis, P., & Findlay, D. M. (2003). The expression of 25-hydroxyvitamin D 24-hydroxylase and 25-hydroxyvitamin D 1 alpha-hydroxylase in human osteoblasts.. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 18 (pp. S409). MINNEAPOLIS, MINNESOTA: AMER SOC BONE & MINERAL RES. 2003 Pan, B., To, L., Farrugia, A., Kostakis, P., Atkins, G., Findlay, D., & Zannettino, A. (2003). Multiple myeloma-derived pro-inflammatory cytokines enhance osteoclastogenesis by increasing the number of RANKL-expressing STRO-1 positive osteoprogenitor cells.. In BLOOD Vol. 102 (pp. 370B). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY. 2003 Zreiqat, H., Howlett, C. R., Zannettino, A., Evans, P., Knabe, C., Schulze-Tanzil, G., & Shakibaei, G. M. (2003). Surface modification of bioceramics affect osteoblastic cells response. In B. BenNissan, D. Sher, & W. Walsh (Eds.), Key Engineering Materials Vol. 240-242 (pp. 707-710). UNIV TECHNOL, SYDNEY, AUSTRALIA: TRANS TECH PUBLICATIONS LTD.
Scopus4 WoS32003 Kostakis, P., Atkins, G., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., . . . Zannettino, A. (2003). The relationship between RANKL expression and osteoblast differentiation in human osteoblasts. In 30th European Symposium on Calcified Tissues, 8-12 May 2003 Vol. Italy (pp. 314-468). Rome, Italy: Springer Science and Business Media LLC.
2002 Atkins, G., Zannettino, A., Kostakis, P., Pan, B., Farrugia, A., Evdokiou, A., & Findlay, D. (2002). Evidence for the maturation-dependent expression of an osteoclastogenic phenotype in human osteoblasts.. In Journal of Bone and Mineral Research Vol. 17 (pp. S446.). San Antonio, Texas: American Society for Bone and Mineral Research. 2002 Atkins, G., Pan, B., Findlay, D., To, L., Evdokiou, A., Labrinidis, A., . . . Zannettino, A. (2002). Zoledronate is anabolic for human osteoblast-like cells. In Journal of Bone and Mineral Research Vol. 17 (pp. S442.). San Antonio, Texas: American Society for Bone and Mineral Research. -
Conference Items
Year Citation 2020 Kobayashi, H., Gieniec, K., Wright, J., Wang, T., Asai, N., Mizutani, Y., . . . Woods, S. (2020). Stromal imbalance of bone morphogenetic protein signaling drives colorectal carcinogenesis. Poster session presented at the meeting of JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY. 2019 Zeissig, M. N., Hewett, D. R., Mrozik, K. M., Panagopoulos, V., Engelhardt, M., To, L. B., . . . Vandyke, K. (2019). Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells. Poster session presented at the meeting of BLOOD. Orlando, FL: AMER SOC HEMATOLOGY.
2019 Opperman, K., Vandyke, K., Psaltis, P., Croucher, P., Noll, J., & Zannettino, A. (2019). Macrophages as a potential therapeutic target: Clodronate-liposome treatment inhibits multiple myeloma tumour establishment in vivo. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
2019 Clark, K., Hewett, D., Panagopoulos, V., Davies, G., & Zannettino, A. (2019). Targeting stromal-derived Gremlin1 to control Multiple Myeloma disease development. Poster session presented at the meeting of CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
2018 Cakouros, D., Hemming, S., Pribadi, C., Zannettino, A., & Gronthos, S. (2018). EPIGENETIC ENZYMES AND THEIR EMERGING ROLE IN MESENCHYMAL STEM CELL LINEAGE DETERMINATION. Poster session presented at the meeting of JOURNAL OF GENE MEDICINE. Univ Technol Sydney, Sydney, AUSTRALIA: WILEY. 2017 Liapis, V., Zinonos, I., Labrinidis, A., Hay, S., Ponomarev, V., Panagopoulos, V., . . . Evdokiou, A. (2017). The hypoxia activated pro-drug evofosfamide exhibits tumour suppressive activity and synergy with chemotherapy against primary and metastatic breast cancers. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. SPANDIDOS PUBL LTD. 2017 Asari, K., Sadras, T., Srihari, S., Fitter, S., An, J., Zannettino, A. C., . . . White, D. L. (2017). in vitro Modelling of Ph-like ALL Fusions Uncovers Novel Kinase-domain Mutations as a Mode of TKI-resistance and Potential Consequence of Targeted TKI Therapy. Poster session presented at the meeting of ANZCHOG. 2016 Asari, K., Heatley, S., Leclercq, T., Fitter, S., Zannettino, A., Hughes, T., & White, D. L. (2016). In vitro Modelling of Therapeutic Resistance to Elucidate Mechanisms of TKI-Resistant High-Risk ALL. Poster session presented at the meeting of .. Noosa, QLD. 2016 Asari, K., Heatley, S., Leclercq, T., Fitter, S., Kok, C. H., Zannettino, A., . . . White, D. L. (2016). Investigating Modes of Therapeutic Resistance via In Vitro Modelling of TKI-resistant High-Risk Philadelphia-chromosome-positive and Philadelphia-chromosome-like Acute Lymphoblastic Leukaemia. Poster session presented at the meeting of Poster Session. Adelaide, SA. 2015 Freeman, B., Kuliwaba, J., Zarrinkalam, M., Jones, C., Shu, C., Colloca, C., . . . Howell, S. (2015). ALLOGENEIC MESENCHYMAL STEM CELLS IMPROVE INDICES OF LUMBAR INTERVERTEBRAL DISC DEGENERATION WITHOUT SITE SPECIFICITY OF INJECTION IN AN OVINE MODEL. Poster session presented at the meeting of OSTEOARTHRITIS AND CARTILAGE. Seattle, WA: ELSEVIER SCI LTD.
WoS12014 Cheung, K. C., Hewett, D., Yeung, D., Tan, C. W., To, L. B., & Zannettino, A. (2014). THE ROLE OF MERTK IN THE PROGRESSION OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) TO MYELOMA (MM). Poster session presented at the meeting of HAEMATOLOGICA. Milan, ITALY: FERRATA STORTI FOUNDATION. 2013 Dharmapatni, A., Coleman, R., Lorimer, M., Zannettino, A., Weedon, H., Wechalekar, M., . . . Crotti, T. (2013). Relationship between Soluble OSCAR and Disease Activity: A 12 Month Study of Newly Diagnosed RA Patients. Poster session presented at the meeting of JOURNAL OF BONE AND MINERAL RESEARCH. Baltimore, MD: WILEY-BLACKWELL. 2013 Forristal, C., Helwani, F., Nowlan, B., Martin, S., Zannetino, A., & Levesque, J. -P. (2013). HYPOXIA INDUCIBLE FACTOR (HIF)-2 alpha ENHANCES PROLIFERATION OF MALIGNANT HAEMATOPOIETIC CELLS IN THE HYPOXIC MALIGNANT BONE MARROW. Poster session presented at the meeting of EXPERIMENTAL HEMATOLOGY. Vienna, AUSTRIA: ELSEVIER SCIENCE INC.
2012 Frith, J., Menzies, D., Cameron, A., Gronthos, S., Zannettino, A., Ghosh, P., & Cooper-White, J. (2012). A novel injectable hydrogel for intervertebral disc regeneration. Poster session presented at the meeting of JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE. WILEY-BLACKWELL. 2012 Crotti, T., Alias, E., Dharmapatni, A., Weedon, H., Zannettino, A., & Smith, M. (2012). EVIDENCE THAT VASCULAR EXPRESSION OF THE ITAM RECEPTOR, OSCAR, IN ACTIVE RHEUMATOID ARTHRITIS IS MODULATED BY INFLAMMATORY MEDIATORS. Poster session presented at the meeting of INTERNAL MEDICINE JOURNAL. WILEY-BLACKWELL. 2008 Vandyke, K., Dewar, A. L., Davis, A. N., Fiuer, S., Hughes, T. P., To, L. B., & Zannettino, A. C. W. (2008). The tyrosine kinase inhibitor dasatinib decreases osteoclast formation and activity in vitro. Poster session presented at the meeting of 30th Annual Meeting of the American Society for Bone and Mineral Research, as published in Journal of Bone and Mineral Research. Montreal, Canada: Wiley.
2003 Atkins, G., Anderson, P., Morris, H., Zannettino, A., Kostakis, P., & Findlay, D. (2003). The expression of 25-hydroxyvitaminD 24-hydroxylase and 25-hydroxyvitaminD 1 alpha-hydroxylase in human osteoblasts. Poster session presented at the meeting of Journal of Bone Mineral Research. Minnesota, USA. 2003 Anderson, P., Atkins, G., Morris, H., Kostakis, P., Findlay, D., & Zannettino, A. (2003). The expression of 25-hydroxyvitaminD 24-hydroxylase and 25-hydroxyvitaminD 1 alpha-hydroxylase in human osteoblasts.. Poster session presented at the meeting of Calcified Tissue International. Rome, Italy: Springer. -
Datasets
Year Citation 2004 Hu, Y., Atkins, G., Zhou, H., Myers, D., Quinn, J., Ly, C., . . . Ng, K. (2004). NM_001004419 Homo sapiens C-type lectin domain family 2, member D (CLEC2D), transcript variant 2, mRNA. 2004 Hu, Y., Atkins, G., Zhou, H., Myers, D., Quinn, J., Ly, C., . . . Ng, K. (2004). NM_013269 Homo sapiens C-type lectin domain family 2, member D (CLEC2D), transcript variant 1, mRNA. — Dutta, A., Zannettino, A., Hewett, D., & l.fink@uq.edu.au. (n.d.). ZANNETTINO_EGA DAA_EGAS00001002850.doc.
Research Funding
Since establishing my laboratory in 2000, I have received competitive research funding of more than AUD$15,019,583 and AUD$2,835,000 in infrastructure funding. Of note, as a CI, I have been awarded a total of 19 NHMRC grants valued in excess of AUD$9,725,058, 1 Cancer Australia grant and 1 International Leukemia Lymphoma Society (US) grant. Furthermore, I have received industry funding of AUD$5 million from sources including Mesoblast, Celgene, Novartis, Zimmer and Johnson & Johnson. A list of the NH&MRC, ARC and other awarded grants are provided below.
Grant Title | Funding | Initiative | Role | First Year Funded | Number of Years | Total Amount ($) of Grant |
---|---|---|---|---|---|---|
Targeting skeletal mTORC1 as a novel approach for the treatment of diet-induced insulin resistance |
Research Support |
Project Grant |
CIA |
2016 |
3 |
586,979.00 |
Why is the bone marrow a “hot-spot” for myeloma plasma cell metastasis: are there Gremlins in the system? |
Research Support |
Project Grant |
CIA |
2016 |
3 |
651,979.00 |
The role of ephrinB1 reverse signalling in osteogenic differentiation during skeletal development and osteoporosis |
Research Support |
Project Grant |
CIB |
2015 |
3 |
548,347.00 |
Understanding clonal evolution in multiple myeloma |
Research Support |
Project Grant |
CIA |
2014 |
3 |
647,111.00 |
Twist-1 inhibits MSC osteoblast differentiation during osteoporosis |
Research Support |
Project Grant |
CIB |
2013 |
3 |
466,044.00 |
Is mTOR a novel target for the treatment of osteoporosis? |
Research Support |
Project Grant |
CIA |
2012 |
3 |
543,675.00 |
EphB-ephrinB mediates MSC bone regeneration |
Research Support |
Project Grant |
CIB |
2012 |
3 |
591,010.00 |
The Role of Hypoxia and Myeloma Disease Progression |
Research Support |
Project Grant |
CIA |
2010 |
3 |
594,582.00 |
Twist-1 Regulation of MSC Growth and Development |
Research Support |
Project Grant |
CIB |
2010 |
3 |
594,582.00 |
Novel strategies for the treatment of bone cancer |
Research Support |
Project Grant |
CIC |
2009 |
3 |
456,304.00 |
Control of premature bony fusion in skull development |
Research Support |
Project Grant |
CIC |
2008 |
3 |
555,855.00 |
Role of TWEAK in bone remodelling |
Research Support |
Project Grant |
CIE |
2007 |
3 |
566,947.00 |
The role of factors that regulate early processes of bone cell development |
Research Support |
Project Grant |
CIB |
2007 |
3 |
485,929.00 |
Chemokines and Myeloma Disease Progression |
Research Support |
Project Grant |
CIA |
2007 |
3 |
665,897.00 |
The role of human osteoblasts in osteoclast formation |
Research Support |
Project Grant |
CIC |
2004 |
3 |
436,450.00 |
Skeletal disease mediated by haematological malignancy |
Research Support |
Project Grant |
CIA |
2004 |
3 |
432,750.00 |
The cells and molecules involved in the formation and activity of human osteoclasts |
Research Support |
Project Grant |
CID |
2001 |
3 |
326,036.00 |
Drug resistance in leukaemia |
Research Support |
Project Grant |
CIC |
2001 |
3 |
362,545.00 |
The Molecular Mechanisms of Bone Destruction in Multiple Myeloma |
Research Support |
Project Grant |
CIA |
2001 |
3 |
212,036.00 |
Grant Title | Funding | Source | Role | First Year Funded | Number of Years | Total Amount ($) of Grant |
---|---|---|---|---|---|---|
Skeletal endocrine signalling in the regulation of glucose metabolism |
Research Support |
Australian Research Council |
CIA |
2016 |
3 |
379,400.00 |
A Tough Resilin based Hydrogel Platform for Repair and Regeneration |
Research Support |
Australian Research Council |
CIB |
2016 |
3 |
358,000.00 |
Tyrosine Kinase Inhibition as a Potential Modality to Control Osteolytic Bone Disease: A New Role for Imatinib Mesylate and Second Generation Bcr-Abl Inhibitors |
Industry Research Support |
Novartis Pharma-ceuticals International |
CIA |
2007 |
3 |
470,000.00 |
Efficacy of Targeting the mTOR and PI3 Kinase Pathways as a Treatment Modality for Myeloma |
Industry Research Support |
Novartis Pharma-ceuticals International |
CIA |
2011 |
1 |
65,000.00 |
Development of a Comprehensive Data Base for Myeloma and Related Disorders |
Industry Support |
Celgene Australia |
CIB |
2010 |
2 |
120,000.00 |
Seed Grant for the Establishment of a Multiple Myeloma and Related Disorders Database |
Research Support |
Cancer Council of South Australia |
CIB |
2010 |
1 |
35,000.00 |
Abl Kinase Inhibition as a Novel Therapy for Myeloma-Associated Bone Loss |
Research Support |
Leukemia & Lymphoma Society - TRP |
CIA |
2009 |
3 |
750,000.00 |
Is elevated N-cadherin expression a poor prognostic indicator in multiple myeloma patients? |
Research Support |
Cancer Australia and Leukaemia Foundation |
CIA |
2010 |
3 |
528,666.00 |
Abl Kinase Inhibition as a Novel Therapy for Malignancy-Associated Bone Loss |
Research Support |
Cancer Council of South Australia |
CIA |
2009 |
1 |
93,000.00 |
Does Modifying the bone marrow stromal micro-environment alter the disease course of multiple myeloma? |
Research Support |
Cancer Council of South Australia |
CIA |
2009 |
1 |
99,171.00 |
Coopertaing genetic changes that drive MM development: the role of SAMSN1 and GLIPR1 tumour suppressor gene |
Research Support |
Cancer Council of South Australia |
CIA |
2015 |
1 |
75,000.00 |
Is mTOR a novel target for the treatment of osteoporosis? |
Research Support |
Research, Robinson Institute Collaborative Grant |
CIA |
2011 |
1 |
75,000.00 |
Understanding the mechanisms of aberrant bone formation in Saethre-Chotzen syndrome patients with Twist-1 mutations |
Research Support |
Research, Robinson Institute Collaborative Grant |
CIB |
2013 |
1 |
65,000.00 |
Understanding the mechanisms of aberrant bone formation in Saethre - Chotzen syndrome patients with Twist-1 mutations |
Research Support |
Project Grant |
CIB |
2007 |
3 |
485,929.00 |
Understanding clonal evolution in multiple myeloma |
Research Support |
Ray and Shirl Norman Trust- HSCGB |
CIA |
2014 |
3 |
300,000.00 |
South Australian Blood Cancer Tumour Bank |
Infra-structure Support |
SA Cancer Research, Medvet, Community donor |
CID |
2013 |
3 |
980,000.00 |
Minimal residual disease (MRD) detection in Multiple Myeloma (MM) patients in complete remission post-autograft: correlation with risk of relapse? |
Research Support |
SA Pathology RAH Contributing Haematologists’ Committee Fund |
CIB |
2015 |
1 |
30,000.00 |
Australian Cancer Research Foundation South Australian Innovative Cancer Imaging And Therapeutics Facility
|
Infra-structure Support |
Australian Cancer Research Foundation |
CIC |
2013 |
1 |
1,800,000.00 |
Bone Marrow Recovery in Acute Lymphoblastic Leukaemia |
Research Support |
Women’s and Children’s Health Foundation |
CIA |
2015 |
2 |
226,426.00 |
An improved technology for isolating human adult stem cells for regenerative therapies |
Research Support |
Adelaide Research and Innovation- Commercial Accelerator Scheme Fund |
CIA |
2013 |
1 |
100,000.00 |
Can The Level of Stromal-Derived Factor-1 (SDF-1α) In Myeloma Patients Predict if They Will Develop Osteolytic Bone Disease? |
Research Support |
RAH/IMVS Clinical Research Grants |
CIA |
2004 |
1 |
18, 500
|
The Identification and Characterization of Novel Regulators of Mesenchymal Stem Cell Differentiation and Lineage Commitment |
Industry Support |
Zymogenetics Inc., Seattle, Washington |
CIA |
1999 |
1 |
90,000.00 |
Characterisation of Novel Drug-Resistance Proteins in Human Leukaemic Cells |
Industry Support |
Medvet Pty Ltd |
CIC |
2000 |
1 |
110,000.00 |
Novel Interaction of the Epidermal Growth Factor-Like Protein DLK with the Growth Arrest-Specific Gene Product GAS-1: Implications for Adipocyte Differentiation |
Research Support |
IMVS/RAH Research Fund |
CIB |
2001 |
1 |
11,000.00 |
Characterisation of RANKL and OPG production by human osteoblastic cells |
Industry Support |
Ely Lilly |
CIB |
2002 |
1 |
20,000.00 |
Utilisation of human osteoblast and osteoclast co-culture models to study anti-resorptive and anabolic agents |
Industry Support |
Ely Lilly |
CIC |
2004 |
1 |
15,000.00
|
Tantalum and osteointegration |
Industry Support |
Zimmer |
CIC |
2002 |
1 |
45,000.00 |
Can The Level of Stromal-Derived Factor-1 (SDF-1α) In Myeloma Patients Predict if They Will Develop Osteolytic Bone Disease? |
Research Support |
Royal Adelaide Hospital-IMVS Research Fund-Clinical Project Grants |
CIA |
2004 |
1 |
23,500.00 |
Mechanisms of Increased Microvessel Density (MVD) In Multiple Myeloma |
Research Support |
IMVS-Contributing Haematologist Committee Fund |
CIA |
2004 |
1 |
36,000.00 |
The Use of Aptamer-Based technologies to Identify Immuno-dominant Epitopes of Factor VIII Which are Responsible for the Development of Anti-Factor VIII Antibodies (Inhibitors) |
Research Support |
IMVS-Contributing Haematologist Committee Fund |
CIA |
2005 |
1 |
30,000.00 |
Can The Level of Stromal-Derived Factor-1 (SDF-1α) In Myeloma Patients Predict if They Will Develop Osteolytic Bone Disease? |
Research Support |
Cancer Council South Australia |
CIA |
2005 |
1 |
149,416.00 |
The Efficacy of Mesenchymal Precursor Cells to Repair Cardiac Defects |
Industry Support |
Angioblast Systems, Ltd |
CIA |
2003 |
2 |
100,000.00 |
Development of Strategies For The Therapeutic Use of Mesenchymal Precursor Cells For Cartilage Repair |
Industry Support |
Mesoblast Ltd |
CIB |
2006 |
2 |
320,692.00 |
Evaluation of the safety and efficacy of Allogeneic Mesenchymal Progenitor Cells (MPC) for the repair of critical size defects in an ovine tibial model |
Industry Support |
Mesoblast Ltd |
CIB |
2006 |
1 |
725,000.00 |
A Preclinical trial of the potential for cultured mesenchymal precursor cells to restore extracellular matrix and normal mechanical function to degenerate intervertebral discs |
Industry/ Research Support |
Mesoblast Ltd/ AusIndustry Grant |
CIC |
2006 |
2 |
794,850.00 |
Research and Services Agreement |
Industry/ Research Support |
Angioblast Ltd/ Mesoblast Ltd |
CIB |
2003 |
3 |
300,000.00 |
BIR (Bortezomib Induction and Reinduction) Study |
Clinical Trial and Research Support |
Johnson & Johnson |
CIB |
2006 |
2 |
445,875.00 |
Kodak chemiluminescence and gel imaging system (4000MM Pro Image Station).
|
Infra-structure Support |
University of Adelaide/NH&MRC Equipment Grant |
CIF |
2008 |
1 |
55,000.00 |
As a former fulltime Medical Scientist in the Department of Haematology, SA Pathology/Institute of Medical and Veterinary Science and Level E Affiliate Titleholder in the School of Medicine, Faculty of Health Science, University of Adelaide, I provided leadership in teaching and supervision in my daily interactions with post-doctoral scientists, research assistants, undergraduate, graduate and post-graduate students. Furthermore, during this period, I provided numerous guest lectures (BBTech students, Uni SA; BHlthSci and MBBS, Uni Adelaide) and successfully mentored numerous honours, masters, PhD and medical students (as part of Department of Medicine’s 4th Year Research Program).
In addition to graduate and post-graduate teaching, since joining the University of Adelaide as Professor of Experimental Haematology, I present undergraduate lectures in courses offered by the Faculty of Health Science ([FHS] Medicine, Physiology, Anatomy and Pathology and Dentistry), Faculty of Science ([FS] Masters program, stem cells) and the University of Sydney (tissue engineering). I provide Honours workshops relating to thesis writing, career opportunities and career development. I also host Physiology III (BHlthSci, FHS) and Principals and Practice of Research III (BSc Advanced, FS) students in my laboratory for small group discovery and research training.
-
Expand
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2021 Principal Supervisor Investigating the effects of calorie restriction on bone marrow adiposity and multiple myeloma progression Doctor of Philosophy Doctorate Full Time Miss Alanah Loretta Bradey 2020 Principal Supervisor Changes in the bone marrow microenvironment with progression to multiple myeloma Doctor of Philosophy Doctorate Full Time Miss Laura Joy Trainor 2020 Co-Supervisor Identification of novel mechanisms that drive the dissemination of multiple myeloma tumour cells Doctor of Philosophy Doctorate Full Time Miss Hayley Bridget Parkinson 2020 Co-Supervisor Investigating the role of Gremlin1 in driving multiple myeloma cancer development and progression Master of Philosophy (Medical Science) Master Full Time Miss Emma Anna-Jane Cheney 2020 Principal Supervisor A novel nanoparticle-based approach for optimising the treatment of Multiple Myeloma Doctor of Philosophy Doctorate Part Time Ms Sadia Munir 2019 Principal Supervisor Novel Treatments with Antibacterial and Wound-healing Properties Doctor of Philosophy under a Jointly-awarded Degree Agreement with Doctorate Full Time Mrs Laurine Dorothea Kaul 2019 Principal Supervisor The roles of the Tam Receptor Family in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Justine Rachel Clark 2019 Principal Supervisor The Yin and Yang of Myeloma Development: The Role of the Bone Marrow Microenvironment in Plasma Cell Dormancy and Activation Doctor of Philosophy Doctorate Full Time Miss Natalya Plakhova 2017 Principal Supervisor Investigating the Role of Resident Bone Macrophages in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mrs Khatora Shanae Opperman -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2017 - 2020 Co-Supervisor CCR1 as a Therapeutic Target in Multiple Myeloma: Preventing Tumour Dissemination and Therapeutic Resistance Doctor of Philosophy Doctorate Full Time Miss Mara Natasha Zeissig 2017 - 2020 Principal Supervisor The Role of Osteoblast-mTORC1 in the Regulation of Glucose Metabolism Doctor of Philosophy Doctorate Full Time Miss Pawanrat Tangseefa 2017 - 2020 Co-Supervisor Generation and Transcriptomic Analysis of HIF-1Alpha and HIF-2Alpha Knockout 5TGM1 Multiple Myeloma Cells Master of Philosophy Master Full Time Mr Yu Chinn Joshua Chey 2015 - 2019 Principal Supervisor The Role of SAMSN1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Ms Natasha Friend 2015 - 2020 Principal Supervisor The Role of Gremlin1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mrs Kimberley Claire Clark 2015 - 2019 Co-Supervisor Smart Materials for Cartilage and Bone Tissue Engineering Doctor of Philosophy Doctorate Full Time Mr Jiabin Zhang 2014 - 2018 Principal Supervisor A Genomic Approach Towards an Understanding of Clonal Evolution and Disease Progression in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Ankit Kumar Dutta 2013 - 2017 Principal Supervisor The Role of TWIST1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Chee Man Cheong 2012 - 2018 Principal Supervisor N-cadherin: Regulation, Role and Therapeutic Targeting in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mr Krzysztof Mrozik 2011 - 2014 Co-Supervisor Mesenchymal Stem Cells for the Treatment of Myocardial Infarction-Induced Ventricular Dysfunction Doctor of Philosophy Doctorate Full Time Dr James David Richardson 2011 - 2018 Co-Supervisor Investigating the Role of HIF-1 and HIF-2 Transcription Factors in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Natalia Magdalena Martin 2010 - 2018 Principal Supervisor The Role of mTORC1 in Mesenchymal Stem Cell Fate Determination, Osteoblast Differentiation and Skeletal Development Doctor of Philosophy Doctorate Part Time Ms Mary Patricia Matthews 2009 - 2013 Co-Supervisor The Role of TWIST-1 in the Regulation of Mesenchymal Stem Cell Growth, Fracture Repair and Bone Loss Doctor of Philosophy Doctorate Full Time Mr Lachlan Cooper 2007 - 2011 Co-Supervisor Cell Lineage, Cell Maturity and BCR-ABL: Factors Which Influence Imatinib Uptake in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Ms Jane Engler 2007 - 2010 Principal Supervisor The Effects of Tyrosine Kinase Inhibition on Bone Remodelling Doctor of Philosophy Doctorate Full Time Dr Kate Vandyke 2006 - 2010 Co-Supervisor The Cardiovascular Reparative Properties of Bone Marrow Mesenchymal Precursor Cells Doctor of Philosophy Doctorate Full Time APrf Peter Psaltis 2005 - 2009 Principal Supervisor Molecular and Cellular Mechanisms of Increased Angiogenesis in Multiple Myeloma: A Role for CXCL12 Doctor of Philosophy Doctorate Full Time Dr Sally Martin 2005 - 2012 Co-Supervisor Cellular and Molecular Mechanisms Involved in the Repair of the Injured Growth Plate in Young Rats Doctor of Philosophy Doctorate Full Time Ms Carmen Macsai 2004 - 2008 Co-Supervisor Factors which Impact on the Response of CML Patients to ABL Kinase Inhibitor Therapy: A Study of Imatinib and Nilotinib Doctor of Philosophy Doctorate Part Time Prof Deborah Lee White 2002 - 2004 Principal Supervisor Mechanisms of Skeletal Disease Mediated by Haematological Malignancies Doctor of Philosophy Doctorate Full Time Miss Beiqing Pan 2001 - 2002 Principal Supervisor CLINICAL MEDICINE Master of Medical Science Master Full Time Miss Beiqing Pan
-
Expand
-
Board Memberships
Date Role Board name Institution name Country 2016 - ongoing — ARCPOH Expert Advisory Committee University of Adelaide — 2015 - ongoing Member Board of Directors Colgate Australian Clinical Dental Research Centre, University of Adelaide Australia 2014 - ongoing Member Advisory Board Robinson Research Institute (RRI), University of Adelaide Australia -
Committee Memberships
Date Role Committee Institution Country 2016 - ongoing Member National Health and Medical Research Council NHMRC Assigners Academy Australia 2015 - ongoing Member National Health and Medical Research Council NHMRC Assigners Academy Australia 2014 - 2015 Chair Research Committee, School of Medical Science University of Adelaide Australia 2012 - ongoing Member Bioscience Pillar Committee South Australian Health and Medical Research Institute (SAHMRI) Australia 2012 - ongoing Member Cell Reprogramming Australia (CRA) — — 2012 - ongoing Member Robinson Institute Transition Management Committee University of Adelaide Australia 2012 - ongoing Member Leukaemia Foundation National Research Program Assessment Panel Leukaemia Foundation Australia 2010 - 2015 Member Scientific Advisory Committee Bone Health Foundation Australia 2010 - ongoing Member Centre for Personalised Cancer Medicine The University of Adelaide Australia 2010 - 2013 Member Fellowships and Scholarships Committee Leukaemia Foundation of Australia Australia 2009 - 2012 Member Medical Assessment Classification Committee SA Pathology — 2007 - 2012 Co-Chair Institutional Biosafety Committee SA Pathology/Institute of Medical and Veterinary Science Australia 2006 - ongoing Member Medical and Scientific Advisory Group Australian Myeloma Foundation Australia -
Memberships
Date Role Membership Country 2010 - ongoing Member Centre for Cancer Biology, SA Pathology Australia 2010 - ongoing Member Centre for Stem Cell Research, University of Adelaide Australia -
Consulting/Advisories
Date Institution Department Organisation Type Country 2013 - ongoing CSIRO — — Australia 2010 - ongoing South Australian Health and Medical Research Institute — — Australia -
Offices Held
Date Office Name Institution Country 2014 - ongoing NHMRC Assigners Academy National Health and Medical Research Council Australia 2012 - ongoing Cancer Biology and Oncology GRP National Health and Medical Research Council Australia 2011 - ongoing Reshaping the Robinson Task Force, Robinson Institute University of Adelaide Australia 2010 - ongoing Oncology GRP National Health and Medical Research Council Australia 2006 - ongoing Cell Biology GRP National Health and Medical Research Council Australia
Connect With Me
External Profiles